Bristol Myers reaches $239 million settlement over psoriasis, MS drugs

Core Insights - Bristol Myers Squibb has reached a $239 million settlement regarding claims that former Celgene shareholders were misled about the prospects of the psoriasis drug Otezla and a multiple sclerosis treatment [1] Group 1 - The settlement amount is $239 million, indicating a significant financial impact on Bristol Myers Squibb [1] - The claims involve allegations of fraud related to the drug Otezla, which is used for treating psoriasis [1] - The case also includes issues surrounding a multiple sclerosis treatment, highlighting potential concerns about the company's product pipeline [1]